Over the past 2 decades, heart failure has become the leading cause of cardiovascular morbidity and mortality. Epidemiological studies show that approximately half of the patients diagnosed with heart failure have a normal ejection fraction.1 The combination of an aging population along with a marked increase in the prevalence of comorbid conditions has resulted in a steady increase in the diagnosis of heart failure with preserved ejection fraction (HFpEF). Compared with patients with left ventricular dysfunction, patients with HFpEF appear to have better survival, although mortality remains significantly higher than that of the healthy population.2 Of equal concern is the high rate of morbidity and frequent hospital admissions associated with HFpEF.3 Despite multiple large-scale clinical trials, no study has identified a treatment that can improve overall survival.4-6
Sayer G, Uriel N. Troponin Assessment in Heart Failure With Preserved Ejection Fraction: Time to Get With the Guidelines. JAMA Cardiol. 2017;2(2):125–126. doi:10.1001/jamacardio.2016.4840
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.